IDH2 and acute myeloid leukemia: The combination of the IDH2 inhibitor enasidenib with AZA/VEN has been evaluated in AML patients with IDH2 mutations, showing promising response rates [107], and further trials assessing the clinical benefit of adding IDH2 inhibitors to AZA/VEN are needed, as durable remissions in IDH2-mutated AML are accompanied by variable molecular persistence [56].